Cerity Partners LLC Sells 70 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Cerity Partners LLC reduced its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 3.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,874 shares of the biotechnology company’s stock after selling 70 shares during the quarter. Cerity Partners LLC’s holdings in United Therapeutics were worth $420,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Vanguard Personalized Indexing Management LLC boosted its stake in shares of United Therapeutics by 0.7% during the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 6,419 shares of the biotechnology company’s stock worth $1,785,000 after acquiring an additional 44 shares during the period. Greenleaf Trust lifted its holdings in United Therapeutics by 5.6% during the 1st quarter. Greenleaf Trust now owns 930 shares of the biotechnology company’s stock worth $208,000 after purchasing an additional 49 shares during the last quarter. Parallel Advisors LLC lifted its holdings in United Therapeutics by 10.4% during the 1st quarter. Parallel Advisors LLC now owns 530 shares of the biotechnology company’s stock worth $119,000 after purchasing an additional 50 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its holdings in United Therapeutics by 0.4% during the 1st quarter. Oregon Public Employees Retirement Fund now owns 13,356 shares of the biotechnology company’s stock worth $2,991,000 after purchasing an additional 50 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. lifted its holdings in United Therapeutics by 6.5% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 899 shares of the biotechnology company’s stock worth $201,000 after purchasing an additional 55 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, EVP Paul A. Mahon sold 2,500 shares of the business’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $243.87, for a total transaction of $609,675.00. Following the sale, the executive vice president now owns 36,599 shares in the company, valued at approximately $8,925,398.13. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other United Therapeutics news, EVP Paul A. Mahon sold 6,000 shares of the company’s stock in a transaction dated Thursday, July 6th. The stock was sold at an average price of $215.19, for a total value of $1,291,140.00. Following the sale, the executive vice president now owns 36,599 shares in the company, valued at approximately $7,875,738.81. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Paul A. Mahon sold 2,500 shares of the company’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $243.87, for a total value of $609,675.00. Following the completion of the sale, the executive vice president now owns 36,599 shares in the company, valued at approximately $8,925,398.13. The disclosure for this sale can be found here. Insiders have sold 20,500 shares of company stock worth $4,684,935 in the last 90 days. Insiders own 12.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on UTHR shares. HC Wainwright reissued a “buy” rating and set a $300.00 price target on shares of United Therapeutics in a report on Thursday, August 3rd. LADENBURG THALM/SH SH lifted their price objective on United Therapeutics from $256.00 to $268.00 and gave the company a “buy” rating in a report on Thursday, August 3rd. Wedbush lifted their price objective on United Therapeutics from $305.00 to $307.00 and gave the company an “outperform” rating in a report on Thursday, August 3rd. StockNews.com initiated coverage on United Therapeutics in a report on Thursday, August 17th. They issued a “buy” rating for the company. Finally, Morgan Stanley lifted their price objective on United Therapeutics from $316.00 to $318.00 and gave the company an “overweight” rating in a report on Thursday, August 3rd. Two equities research analysts have rated the stock with a sell rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $296.44.

United Therapeutics Price Performance

United Therapeutics stock opened at $223.36 on Thursday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.40 and a current ratio of 8.68. United Therapeutics Co. has a 52 week low of $201.65 and a 52 week high of $283.09. The stock has a market capitalization of $10.48 billion, a P/E ratio of 12.58 and a beta of 0.62. The stock has a fifty day moving average of $231.77 and a 200-day moving average of $227.27.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported $5.24 EPS for the quarter, topping analysts’ consensus estimates of $4.57 by $0.67. The company had revenue of $596.50 million during the quarter, compared to analysts’ expectations of $524.18 million. United Therapeutics had a return on equity of 17.52% and a net margin of 41.29%. United Therapeutics’s revenue was up 27.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.41 EPS. On average, sell-side analysts expect that United Therapeutics Co. will post 18.95 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.